Description

SUSTEN SR 400 MG

Indications

SUSTEN SR 400 MG is primarily indicated for the management of various conditions related to hormonal imbalances, particularly in women. It is commonly prescribed for the treatment of secondary amenorrhea, irregular menstrual cycles, and for the maintenance of pregnancy in cases of threatened miscarriage. Additionally, it may be utilized in hormone replacement therapy during menopause and for specific cases of infertility associated with luteal phase defects.

Mechanism of Action

The active ingredient in SUSTEN SR 400 MG is micronized progesterone, a natural hormone that plays a crucial role in the menstrual cycle and in maintaining early stages of pregnancy. SUSTEN SR acts by binding to progesterone receptors in target tissues, leading to a series of biological responses that prepare the endometrium for implantation of a fertilized ovum. It also helps in maintaining the uterine lining during pregnancy, reducing uterine contractions, and modulating immune responses to support fetal development.

Pharmacological Properties

SUSTEN SR 400 MG is characterized by its sustained-release formulation, which allows for a gradual release of micronized progesterone into the bloodstream. This results in stable plasma levels of the hormone, minimizing fluctuations that can occur with immediate-release formulations. The pharmacokinetics of SUSTEN SR indicate that it is well-absorbed after oral administration, with peak plasma concentrations achieved within a few hours. The half-life of micronized progesterone is approximately 5 to 20 hours, depending on individual metabolism.

Contraindications

SUSTEN SR 400 MG should not be used in patients with a known hypersensitivity to progesterone or any of its components. It is contraindicated in individuals with a history of thromboembolic disorders, such as deep vein thrombosis or pulmonary embolism. Additionally, it should be avoided in cases of undiagnosed vaginal bleeding, liver dysfunction, and certain types of cancers, including breast cancer or other hormone-sensitive malignancies. Pregnant women should only use this medication under strict medical supervision.

Side Effects

While SUSTEN SR 400 MG is generally well-tolerated, some patients may experience side effects. Common side effects include headache, dizziness, fatigue, and gastrointestinal disturbances such as nausea or abdominal discomfort. Other potential side effects may include mood changes, breast tenderness, and changes in menstrual flow. Serious adverse effects, although rare, can include severe allergic reactions, liver dysfunction, and thromboembolic events. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of SUSTEN SR 400 MG varies depending on the specific condition being treated. For the management of secondary amenorrhea or irregular menstrual cycles, the typical dosage is 200 to 400 mg daily, taken orally. In cases of threatened miscarriage, a higher dosage may be prescribed, with the treatment duration determined by the healthcare provider. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of therapy to ensure optimal efficacy and safety.

Interactions

SUSTEN SR 400 MG may interact with various medications, potentially altering their effectiveness or increasing the risk of side effects. Drugs that induce or inhibit liver enzymes, particularly cytochrome P450 3A4, can affect the metabolism of micronized progesterone. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions. Special caution should be exercised when using SUSTEN SR in conjunction with anticoagulants, as it may enhance their effects.

Precautions

Before initiating treatment with SUSTEN SR 400 MG, a thorough medical history and physical examination should be conducted. Patients with a history of cardiovascular disease, liver dysfunction, or a family history of breast cancer should be monitored closely during therapy. Regular follow-up appointments are recommended to assess the patient’s response to treatment and to monitor for any adverse effects. Patients should be advised to report any signs of thrombosis, such as swelling or pain in the legs, sudden shortness of breath, or chest pain, immediately.

Clinical Studies

Clinical studies have demonstrated the efficacy of SUSTEN SR 400 MG in various indications. Research indicates that micronized progesterone is effective in restoring menstrual cycles in women with secondary amenorrhea and is beneficial in maintaining early pregnancy in women with a history of recurrent miscarriage. Studies have also shown that the sustained-release formulation provides stable hormone levels, leading to improved patient compliance and satisfaction. Further research is ongoing to explore additional therapeutic applications of micronized progesterone in gynecology and reproductive health.

Conclusion

SUSTEN SR 400 MG is a valuable therapeutic option for managing hormonal imbalances and supporting pregnancy in women. Its sustained-release formulation allows for effective hormone delivery, minimizing fluctuations and enhancing patient adherence. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. A comprehensive approach involving regular monitoring and communication with healthcare providers can optimize treatment outcomes and ensure safety during therapy.